| Similar Articles |
|---|
 |
Chemistry World
September 10, 2013
Phillip Broadwith |
GSK divests Lucozade and Ribena brands GlaxoSmithKline has agreed to sell drinks brands Lucozade and Ribena to Japanese food and beverage maker Suntory. The move is the latest in a series of divestitures.   |
The Motley Fool
July 26, 2011
Cliff D'Arcy |
GSK Showers Shareholders With Cash GlaxoSmithKline, the U.K.'s largest pharmaceutical company, has released its second-quarter results. Thanks to rising earnings and dividends, its shares remain attractively priced, particularly to income-seeking investors. |
The Motley Fool
January 19, 2011
Cliff D'Arcy |
Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements. |
Chemistry World
May 19, 2015
Phillip Broadwith |
GSK commits to HIV research GlaxoSmithKline has reaffirmed its commitment to researching new drugs for HIV -- Aids, by partnering with the University of North Carolina in Chapel Hill, US. |
The Motley Fool
April 15, 2011
Frank Vinluan |
GSK to Shed Weight Loss Drug alli and 18 Others GSK wants to focus on fast-growing "priority brands." |
Chemistry World
September 10, 2014
Emma Stoye |
Cipla targets asthma market with Advair copy Indian pharma company Cipla has begun selling a generic version of GlaxoSmithKline's combination asthma treatment Advair (fluticasone/salmeterol) in Germany and Sweden. |
Chemistry World
April 19, 2013
Phillip Broadwith |
Objections raised to GSK pay-for-delay deals The UK Office of Fair Trading has said that GlaxoSmithKline's deals to delay generic drugs infringed competition laws. |
Chemistry World
April 9, 2014
Emma Stoye |
GSK investigates bribery claims in the Middle East GlaxoSmithKline has been accused of bribing doctors and healthcare officials in Iraq in emails leaked to the Wall Street Journal by a whistleblower. |
Chemistry World
April 25, 2014
Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
The Motley Fool
June 14, 2007
Brian Lawler |
Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry. |
Chemistry World
December 5, 2014
Andy Extance |
GSK cuts US jobs in push for savings 350 of the chemists, engineers and other roles will be lost by April 2015, another 450 by July, and the remainder eliminated by the end of the year. |
Chemistry World
July 2, 2012
Andrew Turley |
$3bn GSK fine sets new industry record The GlaxoSmithKline fine, which relates to antidepressant brands Paxil (paroxetine) and Wellbutrin (bupropion) and diabetes brand Avandia (rosiglitazone), is the largest payment ever made by a drug company. |
The Motley Fool
June 14, 2007
Brian Lawler |
Dueling Fools: GlaxoSmithKline Bull Shares of the pharmaceutical may be temporarily down, but it's not out. |
The Motley Fool
August 4, 2011
Frank Vinluan |
Skin in the Game: How Acne Skin Care Fits GSK's Drug Portfolio Strategy GSK thinks long-term with this acne skin care product. |
Chemistry World
August 29, 2013
Emma Stoye |
Couple charged in GSK corruption investigation A UK consultant and his American wife have been charged in relation to the corruption investigation at GlaxoSmithKline in China. |
Chemistry World
May 16, 2013
Anthony King |
GSK partners Save the Children for Africa project Pharma giant GSK is to partner the international charity Save the Children in a five year deal, which it says aims to help save the lives of one million children. The controversial compact offers a blueprint for how businesses and non-government organizations can work together, says GSK. |
Global Services
July 27, 2007
Imrana Khan |
$44,172: Highest Salary of Indian Tech Grads The average annual salary of an Indian tech employee has grown by 28%, from $6527 in 2006, to $8,500 in 2007. Wages are rising in India, but demand for well-trained IT professionals is still rising faster. |
The Motley Fool
April 5, 2011
Frank Vinluan |
GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep. |
The Motley Fool
April 12, 2011
Brian Orelli |
Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets. |
Chemistry World
August 6, 2014
Hepeng Jia |
GSK's China troubles continue The company faces official prosecution over accusations of bribery and corruption, litigation from fired employees and an upcoming trial of private investigators employed to look into a blackmail attempt. |
Chemistry World
July 20, 2012
Andrew Turley |
GSK secures $3.6bn HGS deal After months of wrangling, GlaxoSmithKline has found enough common ground with Human Genome Sciences for the two to sign up to a $3.6 billion takeover deal. |
The Motley Fool
October 26, 2006
Brian Lawler |
Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth. |
The Motley Fool
February 20, 2007
Todd Wenning |
Is It Time to Get Out? The Indian stock market has had an impressive run over the past five years. But are the good times coming to an end for Indian stocks? |
Chemistry World
October 2011
Bibiana Campos Seijo |
Editorial: Odd Couple McLaren's expertise in building Formula One cars is to be put to use in the manufacture of antibiotics, vaccines and Lucozade in an unlikely alliance between the motor racing team and GlaxoSmithKline. |
The Motley Fool
November 3, 2011
Frank Vinluan |
GSK Settles With Uncle Sam for $3B GSK said the settlement will reduce financial uncertainty for the company and is in the best interest of shareholders. |
Chemistry World
September 25, 2014
Hepeng Jia |
GSK fined 300 million for China corruption After investigation by Chinese police, the British pharmaceutical giant GlaxoSmithKline was fined a record Yuan3 billion ( 300 million pounds) for bribing Chinese doctors and hospital officials. |
The Motley Fool
October 25, 2007
Brian Lawler |
Rope-a-Dope at GSK? Following the negative FDA panel hearings and safety review of diabetes drug Avandia and exchange rate movements against it, revenue fell 3% in the third quarter for GlaxoSmithKline. Operating income and profit were also slightly down. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
The Motley Fool
September 6, 2007
Brian Lawler |
Foolish Fantasy Football: GlaxoSmithKline on Defense In real life, defense wins championships. This stock analyst includes GlaxoSmithKline on his fantasy football investment team, to shield from a punishing sack by the market. |
Chemistry World
April 20, 2009
Phil Taylor |
GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'. |
The Motley Fool
June 21, 2011
Frank Vinluan |
GSK HIV Drug Pipeline Sees Boost as Partner Concert Steers to Clinical Trials GSK and Concert have a possible new treatment for HIV. |
The Motley Fool
June 3, 2011
Frank Vinluan |
GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news. |
IndustryWeek
November 1, 2002
Doug Bartholomew |
Return Of The Native Indian Motorcycle aims for a classic comeback. |
The Motley Fool
September 28, 2007
Brian Lawler |
GSK Helps Secure Future of a Lead Drug GlaxoSmithKline settles a patent infringement case on a lead drug, Avandia, and with that challenger gone, the company is a step closer to securing one of its top franchises. |
The Motley Fool
November 2, 2011
Prabhat Sakya |
AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be? |
BusinessWeek
April 26, 2004
Kripalani & Hamm |
Merger Fever Breaks Out In Bangalore IBM's $150 million purchase of Daksh eServices, the third-largest Indian call center and back-office service provider, may trigger a wave of acquisitions. |
Registered Rep.
February 23, 2009
Kristen French |
News Roundup: Citi Nationalization? UBS Hides Behind Swiss Law; Nigerian Scams Citi Talk of bank nationalization is heating up. |
Pharmaceutical Executive
September 1, 2008
Sarah Houlton |
Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units. |
